146475-23-2 Usage
Uses
Used in Oncology:
Ondansetron hydrochloride is used as an antiemetic agent in oncology for the prevention of nausea and vomiting caused by cancer chemotherapy and radiation therapy. It is effective in managing these side effects, improving the quality of life for patients undergoing cancer treatment.
Used in Surgical Procedures:
In the field of surgery, ondansetron hydrochloride is used as a prophylactic and therapeutic agent to prevent and treat postoperative nausea and vomiting. Its administration helps in reducing the incidence and severity of these symptoms, contributing to a smoother recovery process for patients.
Used in Obstetrics:
Although its use by pregnant women is generally avoided due to potential risks to the fetus, ondansetron hydrochloride may be used in specific cases under the guidance of a healthcare professional, where the benefits of its antiemetic effects outweigh the potential risks.
Side Effects:
While ondansetron hydrochloride is effective in managing nausea and vomiting, it may also cause side effects such as headaches, dizziness, and constipation. Patients should be informed of these potential side effects and advised to report any unusual symptoms to their healthcare provider.
Check Digit Verification of cas no
The CAS Registry Mumber 146475-23-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,6,4,7 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 146475-23:
(8*1)+(7*4)+(6*6)+(5*4)+(4*7)+(3*5)+(2*2)+(1*3)=142
142 % 10 = 2
So 146475-23-2 is a valid CAS Registry Number.
146475-23-2Relevant academic research and scientific papers
Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
-
, (2008/06/13)
The present invention provides novel ondansetron hydrochloride crystalline polymorphic forms and solvates. Processes for making and interconverting the polymorphic forms are also provided. Further provided are pharmaceutical compositions and therapeutic methods using the novel polymorphic forms and hydrates.
